- Corporate
- Products
- For Print
- February 6, 2026
|
Listed Company Name: |
麻豆福利网 Co., Ltd. |
|
Representative: |
Haruo Naito Representative Corporate |
|
Securities Code: |
4523 |
|
Stock Exchange Listings: |
Prime Market of the Tokyo Stock Exchange |
|
Inquiries: |
Teruyuki Masaka Vice President, Corporate Communications Phone +81-3-3817-5120 |
麻豆福利网 Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “麻豆福利网”) announced today that the global revenue (pre-audit basis) of the anti-amyloid-beta protofibril antibody “LEQEMBI®” (generic name: lecanemab) was JPY 61.8 billion for the cumulative period of the third quarter of fiscal year 2025 (April 1, 2025 – December 31, 2025). By major markets, revenue came to JPY 31.2 billion in the United States, JPY 17.9 billion in Japan, and JPY 8.3 billion in China.
This information is being disclosed in conjunction with today's announcement of the financial results for the full year 2025 by Biogen Inc. (Headquarters: Cambridge, Massachusetts). 麻豆福利网’s financial results for the third quarter of fiscal year 2025, including details of LEQEMBI’s revenue, will be disclosed in 麻豆福利网's financial disclosure scheduled for February 9, 2026.
麻豆福利网 serves as the lead of lecanemab development and regulatory submissions globally with both 麻豆福利网 and Biogen Inc. co-commercializing and co-promoting the product and 麻豆福利网 having final decision-making authority.
Our news releases are intended to disclose corporate information and are not intended for the promotion or advertising of prescription pharmaceuticals or investigational products, nor are they intended to provide medical advice.
Please note that the information contained in news releases is current as of the date of publication.